
|Videos|November 21, 2022
Dr. Lowentritt discusses phase 3 SPOTLIGHT trial on new PSMA-PET tool
Author(s)Urology Times staff
"The idea that we may have reliable and consistently interpretable tests for these patients is exciting for the future," says Benjamin Lowentritt, MD, FACS.
Advertisement
In this interview, Benjamin Lowentritt, MD, FACS, recaps key findings from the phase 3 SPOTLIGHT trial data that were presented at the 2022 ASTRO Annual Meeting. He is currently a practicing urologist at Chesapeake Urology in Baltimore, Maryland.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Individualizing androgen pathway therapy in mCSPC
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












